Impact of Chitosan as a disintegrant on the bioavailability of furosemide tablets: In vitro evaluation and in vivo simulation of novel formulations

Pakistan Journal of Pharmaceutical Sciences

Volumn 25, Issue 4, 2012, Pages 815-822

  Rasool, Bazigha Kadhim Abdul ^a   Fahmy, Sahar Abdelsattar ^b   Galeel, Omar Waleed Abdul ^c  

^a DUBAI PHARMACY COLLEGE   (United Arab Emirates)

^b HELWAN UNIVERSITY   (Egypt)

^c National Center of Drug Control and Research   (Iraq)

Author keywords

Chitosan; Disintegrants; Dissolution rate; Furosemide; In vivo simulation; Oral tablets

Indexed keywords

CHITOSAN; FUROSEMIDE; MICROCRYSTALLINE CELLULOSE; POVIDONE; STARCH; CELLULOSE; EXCIPIENT; LOOP DIURETIC AGENT;

ARTICLE; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; TABLET; WATER TRANSPORT; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; CHEMISTRY; COMPUTER SIMULATION; HARDNESS; METHODOLOGY; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; POWDER; PRESSURE; SOLUBILITY;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; COMPUTER SIMULATION; EXCIPIENTS; FUROSEMIDE; HARDNESS; HARDNESS TESTS; MODELS, BIOLOGICAL; POVIDONE; POWDERS; PRESSURE; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SOLUBILITY; STARCH; TABLETS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84871893289     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Allen LV, Popvich NG and Ansel HC (2011). Solid dosage forms and solid modified-release drug delivery systems. In: Troy DB (editor). Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, 9th ed., Lippincott Williams & Wilkins, Philadelphia, PA, pp. 225-256.
2. Amrutkar JR and Gattani SG (2009). Chitosanchondroitin sulfate based matrix tablets for colon specific delivery of indomethacin. AAPS Pharm. Sci. Tech., 10: 670-677.
3. Andries FM, Mingna S and Melgardt M (2003). Effect of compression force, humidity and disintegrant concentration on the disintegration and dissolution of directly compressed furosemide tablets using croscarmellose sodium as disintegrant. Trop. J. Pharm. Res., 2(1): 125-135.
4. Aulton ME (2002). Pharmaceutics the Science of Dosage Form Design. 2nd ed., Churchill Livingstone, Edinburgh, pp. 404-410.
5. Beermann B, Dalen E and Lindstrom B (1978). Bioavailability of two furosemide preparations. Br. J. Clin. Pharmac., 6: 537-538.
6. Benita BS, Shani J, Abdulrazik M and Samuni A (1984). Controlled release of radioprotective agents from matrix tablets-effect of preparative conditions on release rates. J. Pharm. Pharmacol., 36: 222-228.
7. Bhise S[D12], Chaulang G, Patel P, Patel B, Bhosale A and Hardikar S (2009). Superdisintegrants as Solubilizing agent. Res. J. Pharm. Tech., 2(2): 387-391.
8. Bi Y, Yonezawa Y and Sunada H (1999). Rapidly disintegrating tablets prepared by the wet compression method: mechanism and optimization. J. Pharm. Sci., 88: 1004-1010.
9. Caramella C, Ferrari F, Bonferoni MC and Ronchi M (1990). Disintegrants in solid dosage forms. Drug Dev. Ind. Pharm., 16: 2561-2577.
10. Chaulang G, Patel P, Hardikar S, Kelkar M, Bhosale A and Bhise S (2009). Formulation and evaluation of solid dispersions of furosemide in sodium starch glycolate. Trop. J. Pharm. Res., 8(1): 43-51.
11. Desai DS, Rubitski BA, Varia SA and Newman AW (1993). Physical interactions of magnesium stearate with starch-derived disintegrants and their effects on capsule and tablet dissolution. Int. J. Pharm., 91: 217-226.
12. Ferrari F, Bertoni M, Bonferoni MC, Rossi S, Caramella C and Nyström C (1996). Investigation on bonding and disintegration properties of pharmaceutical materials. Int. J. Pharm., 136: 71-79.
13. Gabrielsson J and Weiner D (2007). Modeling Strategy: Pharmacokinetic and Pharmacodynamic Data Analysis, Concepts and Application, 4th ed., Swedish Pharmaceutical Press, Stockholm, 960-1012.
14. Garnpimol CR, Parichat C, Sunibhond P and Piamsak M (1994). Chitin and chitosan as disintegrants in paracetamol tablets. Drug Dev. Ind. Pharm., 20(13): 2109-2134.
15. Ganderton D (1969). The effect of distribution of magnesium stearate on the penetration of a tablet by water. J. Pharm. Pharmacol., 21: 9S-18S.
16. Granero GE, Longhi MR, Mora MJ, Junginger HE, Midha, KK, Shah VP, Stychansky S, Dressman JB and Barends DM (2010). Biowaiver monographs for immediate release solid oral dosage forms: Furosemide. J. Pharm. Sci., 99(6): 2544-2556.
17. Guyot H (1992). The disintegration and disintegrating agent. S.T.P. Pharma. Sci., 2(6): 445-462.
18. Hoshang MU, Joseph BS and Roger LS (1988). The effect of the wet granulation process on drug dissolution. Drug Dev. Ind. Pharm., 14(10): 1327-1349.
19. Lachman L, Herbert A and Kanig J (1987). The Theory and Practice of Industrial Pharmacy. 3rd ed., Varghese Publishing House, Philadelphia, pp. 430-456.
20. Keith M (1986). Compression and Consolidation of Powdered Solids. In: Lachman L, Liberman HA and Kang JL, The Theory and Practice of Industrial Pharmacy, 3rd ed., Lea and Febiger, Philadelphia, p.73.
21. Khan KA and Rhodes CT (1976). Effect of variation in compaction force on properties of six direct compression tablet formulations. J. Pharm. Sci., 65: 1835-1837.
22. Kokil S, Patil P, Mahadik K and Paradkar A (2005). Studies on spray-dried mixtures of chitosan and hydrolyzed gelatin as tablet binder: A technical note. AAPS Pharm. Sci. Tech., 6(3): E437-E443.
23. Moffate AC (1986). Clark's Isolation and Identification of Drugs. 2nd ed., Pharmaceutical Society of Great Britain, London, pp. 428-429, 740-741, 936-937.
24. Okhamafe AO, Igboechi A and Obaseki TO (1991). Celluloses extracted from groundnut shell and rice husk 1: Preliminary physicochemical characterization. Pharm. World J., 8(4): 120-130.
25. Ponto LL and Schoenwald RD (1990). Furosemide (frusemide) a pharmacokinetic/pharmacodynamic review (Part I). Clin. Pharmacokinet., 18: 381-408.
26. Riffat Y, Shoaib MH and Khalid H (2005). Comparative study of different formulations of atenolol. Pak. J. Pharm Sci., 18(1): 47-51.
27. Ritthidej GC, Chomto P, Pummangura S and Menasveta P (1994). Chitin and chitosan as disintegrants in paracetamol tablets. Drug Dev. Ind. Pharm., 20(13): 2109-2134.
28. Rubinstein MH (1980). The effect of disintegrants and processing on the bioavailability of frusemide from compressed tablets. Drug Dev. Ind. Pharm., 6: 105-19.
29. Rubenstein MH and Rughani JM (1989). The effect of four particle characteristics on the dissolution rate, tablet binders on bioavailability of frusemide. Drug Dev. Ind. Pharm., 15: 621-627.
30. Ruiz NR and Ghaly ES (1997). Mechanism of drug release from matrices with aqueous dispersion of ethyl cellulose. Drug Dev. Ind. Pharm., 23: 113-17.
31. Singh MK, Prajapati SK, Mahor A, Rajput N and Singh R (2011). Chitosan: A novel excipient in pharmaceutical formulation: a review. Int. J. Pharm. Sci. Res., 2(9): 2266-2277.
32. Struszczyk H, Wawro D and Niekraszewicz A (1991). Biodegradability of chitosan fibres, In: Brine CJ, Sandford PA, Zikakis JP, Advances in Chitin and Chitosan, 1st ed., Elsevier Applied Science, London, pp. 580-585.
33. Zhao N and Augsburger LL (2005). The Influence of swelling capacity of super-disintegrants in different pH media on the dissolution of hydrochlorothiazide from directly compressed tablets. AAPS Pharm. Sci. Tech., 6(1): E120-E126.
34. Zhang[D13] Y, Law Y and Chakrabarti S (2003). Physical properties and compact analysis of commonly used direct compression binders. AAPS Pharm. Sci. Tech., 4(4): E62.